pirenzepine has been researched along with Dyskinesia, Drug-Induced in 74 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 9.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| "The high acquisition cost of olanzapine is offset by reductions in other treatment costs in patients with schizophrenia." | 8.80 | Olanzapine. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1999) |
| "This open-label pilot study explored the antiemetic activity of olanzapine, an atypical antipsychotic, in patients with advanced cancer requiring opioid analgesics for pain." | 7.71 | A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. ( Cooper, M; Donaghy, K; Dugan, W; Holtsclaw, E; Kirsh, KL; Lundberg, J; Passik, SD; Theobald, D, 2002) |
| "Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile." | 6.69 | Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000) |
| " To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored." | 6.40 | Olanzapine in the long-term treatment of schizophrenia. ( Kane, J, 1999) |
| "To evaluate and compare the drug response and side effects of adolescents with schizophrenia treated with olanzapine, risperidone, and haloperidol." | 5.10 | Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. ( Apter, A; Bloch, Y; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Ratzoni, G; Reidman, J; Tyano, S; Weizman, R, 2003) |
| " Patients with schizophrenia and related disorders (ICD-10) who were taking haloperidol (N = 94; mean dose = 12." | 5.09 | Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. ( Alvarez, N; Costa e Silva, JA; Cousins, L; Gattaz, WF; Larach, V; Mazzotti, G; Oliva, D; Ospina, J; Starkstein, S; Taylor, CC; Tohen, M; Tran, PV; Wang, J, 2001) |
| "5 mg/day [Olz-H]) to a dosage range of haloperidol (15 +/- 5 mg/day [Hal]) and to placebo in the treatment of 335 patients who met the DSM-III-R criteria for schizophrenia." | 5.08 | Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. ( Beasley, CM; Hamilton, S; Sanger, T; Satterlee, W; Tollefson, G; Tran, P, 1996) |
| "Data were analyzed from three actively controlled and blind long-term responder studies of subjects meeting DSM-III-R criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder treated with olanzapine (N = 707, up to 20 mg/day, 237 median days of exposure) or haloperidol (N = 197, up to 20 mg/day, 203 median days of exposure) who did not have evidence of tardive dyskinesia at baseline." | 5.08 | Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. ( Beasley, CM; Potvin, JH; Tamura, RN; Tollefson, GD; Tran, PV, 1997) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| "The high acquisition cost of olanzapine is offset by reductions in other treatment costs in patients with schizophrenia." | 4.80 | Olanzapine. A pharmacoeconomic review of its use in schizophrenia. ( Foster, RH; Goa, KL, 1999) |
| "This open-label pilot study explored the antiemetic activity of olanzapine, an atypical antipsychotic, in patients with advanced cancer requiring opioid analgesics for pain." | 3.71 | A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. ( Cooper, M; Donaghy, K; Dugan, W; Holtsclaw, E; Kirsh, KL; Lundberg, J; Passik, SD; Theobald, D, 2002) |
| " The patients were treated with conventional antipsychotics for seven days after admission and were then randomised to the treatment arms with risperidone (4 mg/day) or with olanzapine (10 mg/day) at a fixed dosage in the first week and thereafter in flexible dosages for the remaining seven weeks." | 2.71 | Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia. ( Kores Plesnicar, B; Krajnc, I; Tomori, M; Zalar, B, 2003) |
| "Olanzapine is a novel antipsychotic effective in reducing positive and negative symptoms of schizophrenia and with a safe side-effect profile." | 2.69 | Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. ( Brenner, R; Concepcion, NM; Florita, CD; Kaur, A; Madhusoodanan, S; Menon, G; Nunez, G; Reddy, H; Suresh, P, 2000) |
| " Surprisingly, there has been little relationship between the pivotal trials designed for FDA approval and current dosing strategies in broader clinical settings." | 2.41 | New antipsychotic medications: more than old wine and new bottles. ( Schulz, SC, 2000) |
| "Although the risk of developing lethal neuroleptic malignant syndrome may be diminished with atypical drugs, clinicians must remain alert to the signs of this disorder." | 2.41 | Movement disorders associated with atypical antipsychotic drugs. ( Campbell, EC; Caroff, SN; Mann, SC; Sullivan, KA, 2002) |
| "Risperidone appears to be an effective therapy, but several authors report cases of TD during treatment." | 2.41 | Tardive dyskinesias and antipsychotics: a review. ( Bayle, FJ; Chereau, I; Lancon, C; Llorca, PM, 2002) |
| "Most traditional neuroleptics have a narrow therapeutic-to-toxic index, and thus, the novel antipsychotics are the result of a search to substantially widen the distance between the dose that treats psychosis and the one that produces adverse effects." | 2.40 | The relationship of pharmacology to side effects. ( Casey, DE, 1997) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| " To provide the therapeutic benefits of maintenance medication without its drawbacks, intermittent dosing and long-term therapy with reduced doses of conventional medications have been explored." | 2.40 | Olanzapine in the long-term treatment of schizophrenia. ( Kane, J, 1999) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| " Relatively little information on adverse events (AEs), specifically in children or adolescents taking atypical antipsychotics, is available." | 1.31 | Effects of development on olanzapine-associated adverse events. ( Martin, A; McGlashan, TH; Spector, SG; Woods, SW, 2002) |
| "A 21-year-old man with the diagnosis of paranoid schizophrenia was admitted to our clinic with cervical dystonia developing at the end of the first year of olanzapine therapy." | 1.31 | Tardive dystonia associated with olanzapine therapy. ( Afsar, N; Aktan, S; Gunal, DI; Onultan, O, 2001) |
| "Converging evidence indicates that, in controlled drug trials, individuals receiving novel antipsychotic medications have fewer adverse effects than those receiving conventional antipsychotic medications." | 1.31 | Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. ( Bromet, EJ; Davidson, M; Rabinowitz, J, 2001) |
| " Here we report results of the association of oral chewing movements in rats with chronic administration of two new antipsychotic drugs, olanzapine and sertindole." | 1.30 | Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. ( Gao, XM; Sakai, K; Tamminga, CA, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (43.24) | 18.2507 |
| 2000's | 42 (56.76) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benazzi, F | 1 |
| Lykouras, L | 2 |
| Agelopoulos, E | 1 |
| Tzavellas, E | 1 |
| Truöl, S | 1 |
| Von Hippel, C | 1 |
| Raape, J | 1 |
| König, F | 1 |
| Woods, SW | 2 |
| Martin, A | 1 |
| Spector, SG | 1 |
| McGlashan, TH | 1 |
| Schwartz, TL | 1 |
| Saba, M | 1 |
| Hardoby, W | 1 |
| Virk, S | 1 |
| Masand, PS | 1 |
| Bella, VL | 1 |
| Piccoli, F | 1 |
| Kucerová, H | 1 |
| Kores Plesnicar, B | 1 |
| Zalar, B | 1 |
| Tomori, M | 1 |
| Krajnc, I | 1 |
| Koch, HJ | 1 |
| Szecsey, A | 1 |
| Vogel, M | 1 |
| Fischer-Barnicol, D | 1 |
| Gothelf, D | 1 |
| Apter, A | 1 |
| Reidman, J | 1 |
| Brand-Gothelf, A | 1 |
| Bloch, Y | 1 |
| Gal, G | 1 |
| Kikinzon, L | 1 |
| Tyano, S | 1 |
| Weizman, R | 1 |
| Ratzoni, G | 1 |
| Nel, A | 1 |
| Harvey, BH | 1 |
| Yeh, IN | 1 |
| Lin, SK | 1 |
| Tsai, CJ | 1 |
| Liu, HC | 1 |
| Meltzer, HY | 1 |
| Fibiger, HC | 1 |
| Beasley, CM | 3 |
| Tollefson, G | 1 |
| Tran, P | 1 |
| Satterlee, W | 1 |
| Sanger, T | 1 |
| Hamilton, S | 1 |
| Casey, DE | 3 |
| Daniel, DG | 1 |
| Egan, M | 1 |
| Issa, F | 1 |
| Tollefson, GD | 4 |
| Tamura, RN | 2 |
| Tran, PV | 3 |
| Potvin, JH | 2 |
| Hamilton, SH | 2 |
| Kuntz, AJ | 1 |
| Andersen, SW | 1 |
| Beasley, C | 1 |
| Littrell, KH | 1 |
| Johnson, CG | 1 |
| Littrell, S | 1 |
| Peabody, CD | 1 |
| O'Brien, J | 1 |
| Barber, R | 1 |
| Andersson, C | 1 |
| Chakos, M | 1 |
| Mailman, R | 1 |
| Lieberman, J | 1 |
| Almeida, OP | 1 |
| Lewis, R | 1 |
| Gao, XM | 1 |
| Sakai, K | 1 |
| Tamminga, CA | 1 |
| Bruneau, MA | 1 |
| Stip, E | 1 |
| Kinon, BJ | 1 |
| Jeste, DV | 2 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Soutullo, CA | 1 |
| Keck, PE | 1 |
| McElroy, SL | 1 |
| Breier, A | 1 |
| Kane, JM | 1 |
| Kane, J | 1 |
| Dellva, MA | 1 |
| Morgenstern, H | 1 |
| Glazer, WM | 2 |
| Ferguson, K | 1 |
| Herrán, A | 1 |
| Vázquez-Barquero, JL | 1 |
| Malliori, M | 1 |
| Christodoulou, GN | 1 |
| Berk, M | 1 |
| Brook, S | 1 |
| Trandafir, AI | 1 |
| Dunayevich, E | 1 |
| Strakowski, SM | 1 |
| Foster, RH | 1 |
| Goa, KL | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Ananth, J | 1 |
| Kenan, J | 1 |
| Schulz, SC | 1 |
| Khan, M | 1 |
| Farver, D | 1 |
| Simpson, GM | 1 |
| Durst, R | 1 |
| Katz, G | 1 |
| Zislin, J | 1 |
| Raskin, S | 1 |
| Kalman, I | 1 |
| Madhusoodanan, S | 1 |
| Brenner, R | 1 |
| Suresh, P | 1 |
| Concepcion, NM | 1 |
| Florita, CD | 1 |
| Menon, G | 1 |
| Kaur, A | 1 |
| Nunez, G | 1 |
| Reddy, H | 1 |
| Naber, D | 1 |
| Möller, HJ | 1 |
| Haberfellner, EM | 1 |
| Manson, AJ | 1 |
| Schrag, A | 1 |
| Lees, AJ | 1 |
| Mullen, A | 1 |
| Roberts, RC | 1 |
| Esel, E | 1 |
| Turan, MT | 1 |
| Sofuoglu, S | 1 |
| Gönül, AS | 1 |
| Price, PL | 1 |
| Shulman, RW | 1 |
| Birkett, MA | 1 |
| Kiesler, GM | 1 |
| Wood, AJ | 1 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Voirol, P | 1 |
| Agarwal, V | 1 |
| Kumar, P | 1 |
| Ipekçi, S | 1 |
| Birsöz, S | 1 |
| Costa e Silva, JA | 1 |
| Alvarez, N | 1 |
| Mazzotti, G | 1 |
| Gattaz, WF | 1 |
| Ospina, J | 1 |
| Larach, V | 1 |
| Starkstein, S | 1 |
| Oliva, D | 1 |
| Cousins, L | 1 |
| Tohen, M | 1 |
| Taylor, CC | 1 |
| Wang, J | 1 |
| Sa, DS | 1 |
| Lang, AE | 1 |
| Smith, RC | 1 |
| Infante, M | 1 |
| Singh, A | 1 |
| Khandat, A | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
| Gunal, DI | 1 |
| Onultan, O | 1 |
| Afsar, N | 1 |
| Aktan, S | 1 |
| Rabinowitz, J | 1 |
| Bromet, EJ | 1 |
| Davidson, M | 1 |
| Caroff, SN | 1 |
| Mann, SC | 1 |
| Campbell, EC | 1 |
| Sullivan, KA | 1 |
| Llorca, PM | 1 |
| Chereau, I | 1 |
| Bayle, FJ | 1 |
| Lancon, C | 1 |
| Passik, SD | 1 |
| Lundberg, J | 1 |
| Kirsh, KL | 1 |
| Theobald, D | 1 |
| Donaghy, K | 1 |
| Holtsclaw, E | 1 |
| Cooper, M | 1 |
| Dugan, W | 1 |
| Conus, P | 1 |
| Zullino, D | 1 |
| Baumann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quetiapine in the Treatment of Psychotic Depression - a Pilot Study[NCT00751504] | Phase 3 | 16 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for pirenzepine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Olanzapine: a new typical antipsychotic drug.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pirenzepine; Ps | 1996 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
The relationship of pharmacology to side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; D | 1997 |
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Clozapine; Dibenzothiazepines; Dopamine | 1998 |
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.
Topics: Adolescent; Adolescent Psychiatry; Age Factors; Antipsychotic Agents; Benzodiazepines; Cholinergic F | 1998 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clinical Tri | 1998 |
The routine use of atypical antipsychotic agents: maintenance treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Caregivers; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pir | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Tardive dyskinesia and atypical antipsychotic drugs.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 1999 |
Tardive dyskinesia in affective disorders.
Topics: Adult; Affective Disorders, Psychotic; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 1999 |
Olanzapine in the long-term treatment of schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; H | 1999 |
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Costs and Cost Analysis; Dyskinesia, Drug-Induced; Humans; Ol | 1999 |
New antipsychotic medications: more than old wine and new bottles.
Topics: Agranulocytosis; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzot | 2000 |
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dysk | 2000 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
The treatment of tardive dyskinesia and tardive dystonia.
Topics: Adult; Akathisia, Drug-Induced; Algorithms; Antipsychotic Agents; Benzodiazepines; Clozapine; Decisi | 2000 |
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Movement disorders associated with atypical antipsychotic drugs.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 2002 |
Tardive dyskinesias and antipsychotics: a review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Humans; Ola | 2002 |
14 trials available for pirenzepine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-I | 2003 |
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Depression; Dopamine Antagonists; Dyskinesia, Dru | 2003 |
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Dose-Respon | 1996 |
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Administration | 1997 |
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; | 1997 |
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Ben | 1999 |
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Topics: Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Haloperidol; H | 1999 |
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cannabis; Double-Blind Method; Dyskinesia, Drug-Induce | 1999 |
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Administration Schedule; | 2000 |
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Drug Interactions; Dyskinesia, Drug- | 2000 |
Low-dose olanzapine for levodopa induced dyskinesias.
Topics: Aged; Benzodiazepines; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male | 2000 |
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Weight; Clozapine; Double-Blind M | 2001 |
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperi | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
41 other studies available for pirenzepine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Huntington Disease; Male; M | 2002 |
Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; O | 2002 |
[Improvement of tardive dyskinesia after treatment with olanzapine].
Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Com | 2002 |
Effects of development on olanzapine-associated adverse events.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Antipsychotic Agents; Basal | 2002 |
Use of atypical antipsychotics in a Veterans Affairs hospital.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, Drug-Induced; Female; Hospitals | 2002 |
Olanzepine-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Olanza | 2003 |
Olanzapine and improvement of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; Hum | 2002 |
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.
Topics: Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Dysk | 2003 |
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induce | 2003 |
Rapid onset of dyskinesia induced by olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; O | 2003 |
Olanzapine motor side effect.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Olanzapine; Pirenzepine | 1997 |
Marked reduction of tardive dyskinesia with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Olanzapine; Ph | 1998 |
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hallucinations; Humans; Male; | 1998 |
Olanzapine for the treatment of tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Biperiden; Dyskinesia, Drug-Induced; Female; Haloperido | 1998 |
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Imidazoles; I | 1998 |
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Female; Humans; Middle A | 1998 |
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.
Topics: Adult; Alcoholism; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Mi | 1999 |
Tardive dyskinesia associated with olanzapine.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Humans; Olanza | 1999 |
Improvement of tardive dyskinesia following treatment with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Olanzapi | 1999 |
Olanzapine-induced tardive dystonia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dyskinesia, Drug-Induced; Dystonia; | 1999 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
Tardive dyskinesia associated with olanzapine monotherapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Dystonia; Humans; Male; Olan | 1999 |
Tardive dyskinesia in older patients.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiaz | 2000 |
Rabbit syndrome treated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Humans; Olanzapine; | 2000 |
Olanzapine and tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Pi | 1999 |
[Atypical antipsychotics].
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost-Benefit Analysis; | 2000 |
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dopamine Antagonists; Dyskinesia, Drug-Induced; Flupen | 2000 |
Risperidone and tardive dyskinesia: a case of blepharospasm.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blepharospasm; Dyskinesia, Drug-Induced; Humans; Male; | 2000 |
Effect of chronic olanzapine treatment on striatal synaptic organization.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Haloperidol; Male; Neostri | 2001 |
Improvement of tardive dyskinesia in a bipolar patient with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dyskinesia, Drug-Induced; Female; Humans; M | 2000 |
Olanzapine to treat the acute mania of bipolar disorder.
Topics: Acute Disease; Affect; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disord | 2000 |
Drug review "surprises" reader.
Topics: Aged; Alanine Transaminase; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug In | 2000 |
Ondansetron for tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Dyskinesia, Drug-Induced; Human | 2001 |
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; | 2001 |
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.
Topics: Adult; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Neurologic Examination; Olanzapine; | 2001 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Hallucinations; Hu | 2001 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |
Tardive dystonia associated with olanzapine therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Humans; Male; Olanzapine; Pi | 2001 |
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder, Majo | 2001 |
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Benzodiazepines; Dyskinesia, Drug-Induced; | 2002 |
Clozapine is more efficacious for tongue dystonia than olanzapine.
Topics: Adult; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Olanzapine; P | 2002 |